Incyte Secures FDA Approval for Extended‑Release Jakafi XR
Incyte Corporation has obtained U.S. Food and Drug Administration (FDA) approval for a once‑daily, extended‑release formulation of its JAK1/JAK2 inhibitor, ruxolitinib, marketed as Jakafi XR. The approval expands the therapeutic indications of ruxolitinib to include:
- Adult patients with intermediate‑ or high‑risk myelofibrosis.
- Adult patients with polycythemia vera who have not tolerated hydroxyurea.
- Patients aged 12 years and older with steroid‑refractory acute or chronic graft‑versus‑host disease (GVHD) after one or two lines of systemic therapy.
The new formulation, a 55‑mg once‑daily tablet, delivers a therapeutic effect equivalent to the twice‑daily 25‑mg immediate‑release regimen. This equivalence was established in a bioequivalence study that demonstrated comparable plasma concentration‑time profiles and trough concentrations, ensuring maintained efficacy and safety.
Scientific Rationale and Mechanism of Action
Ruxolitinib is a potent, selective inhibitor of Janus kinase (JAK) 1 and 2. By blocking these kinases, the drug disrupts cytokine signaling pathways that drive proliferation of abnormal myeloid precursors in myeloproliferative neoplasms (MPNs) and modulates the hyperactive immune response seen in GVHD. The extended‑release formulation sustains therapeutic plasma levels over a 24‑hour period, reducing peak‑to‑trough fluctuations associated with twice‑daily dosing. This pharmacokinetic profile is expected to improve patient adherence and potentially reduce dosing‑related side‑effects, such as myelosuppression and gastrointestinal disturbances, without compromising the drug’s antineoplastic or immunomodulatory efficacy.
Clinical Evidence Supporting the Approval
The FDA approval was based on a phase III, randomized, double‑blind, bioequivalence study (N = ~300) comparing the 55‑mg once‑daily tablet to the 25‑mg twice‑daily regimen in patients with myelofibrosis or polycythemia vera. Key findings included:
| Parameter | Jakafi XR (55 mg q.d.) | Jakafi (25 mg b.i.d.) |
|---|---|---|
| Cmax | 1.1‑fold higher | Reference |
| Cmin | 0.95‑fold | Reference |
| AUC0‑24 | 0.98‑fold | Reference |
| Adverse events | Comparable incidence (≈ 20 %) | Comparable incidence (≈ 21 %) |
The study met the predefined bioequivalence criteria (90 % confidence intervals for Cmax, Cmin, and AUC falling within 0.80–1.25). Efficacy endpoints—such as reduction in spleen volume and improvement in symptom scores—were preserved across both formulations, confirming that the extended‑release tablet does not compromise clinical benefit.
Regulatory Pathway and Timeline
Incyte submitted a New Drug Application (NDA) amendment in early 2024, incorporating the bioequivalence data, a detailed pharmacokinetic model, and post‑marketing pharmacovigilance plans. The FDA’s Center for Drug Evaluation and Research (CDER) reviewed the application in a 90‑day window, ultimately granting approval on May 8, 2026. The company will launch the product through pharmacy orders starting the same day, ensuring a seamless transition for clinicians already prescribing the immediate‑release formulation.
Market Implications and Investor Response
The approval was well‑received by the market, as evidenced by a modest uptick in Incyte’s share price immediately following the announcement. Analysts suggest that the once‑daily dosing will broaden the drug’s appeal in both the myelofibrosis and GVHD segments, potentially increasing market penetration and providing a competitive edge over other JAK inhibitors that require multiple daily administrations.
Conclusion
Incyte’s extended‑release Jakafi XR represents a clinically and commercially significant development. By maintaining the established efficacy profile while simplifying the dosing regimen, the formulation addresses a critical unmet need for patients with MPNs and GVHD. The FDA’s approval reinforces Incyte’s commitment to delivering scientifically robust, patient‑centric therapies across hematology and immunology therapeutic areas.
